Advertisement
CRSP vs SANA
Which Stock Would AI Choose? CRISPR Therapeutics (CRSP) vs. Sana Biotechnology (SANA) Stock Comparison
Key Takeaways
- CRISPR Therapeutics (CRSP) is a commercial-stage gene-editing company whose approved therapy, Casgevy, is scaling revenue, while Sana Biotechnology (SANA) remains a preclinical, cash-constrained developer of engineered-cell therapies.
- CRSP's relative performance has been steadier, supported by a roughly $2.4 billion cash position, whereas SANA has relied on fresh equity raises to extend its runway.
- CRSP's growth is anchored in a single marketed product and a deep clinical pipeline; SANA's value is tied to early, high-upside programs in type 1 diabetes and in vivo CAR T.
- Both companies remain unprofitable, making clinical catalysts and funding durability the dominant drivers of market positioning.
- For more detail, explore CRSP Major News and CRSP Today's Price Move, as well as SANA Major News and SANA Today's Price Move.
- For a data-driven perspective on current market opportunities, explore Trending AI Robots.
Introduction
Both CRSP and SANA operate at the frontier of genetic medicine, yet they sit at very different stages of the commercial lifecycle. This stock comparison is relevant to investors weighing an established, product-generating gene-editing franchise against an earlier-stage, higher-risk cell-engineering platform. Because the two companies share broad exposure to the biotechnology sector but diverge sharply on revenue, cash reserves, and pipeline maturity, a side-by-side review of their relative performance and market positioning can help both growth-oriented and risk-tolerant investors frame the trade-offs involved.
CRSP Overview and Recent Performance
CRISPR Therapeutics is a gene-editing company best known for Casgevy, the world's first approved CRISPR-based therapy, developed and commercialized with Vertex Pharmaceuticals for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Recent market activity has been shaped by accelerating Casgevy uptake: partner Vertex reported roughly $76 million in Casgevy sales in the most recent quarter, a sharp sequential and year-over-year increase. CRSP's own collaboration revenue has grown accordingly, though absolute figures remain modest. The company reported a narrower quarterly loss than a year earlier, reflecting disciplined cost management.
Sentiment has also been influenced by pipeline progress. CRISPR is advancing zugo-cel, an "off-the-shelf" allogeneic (donor-derived) CAR T therapy, across autoimmune disease and blood cancers, and is prioritizing in vivo (inside-the-body) candidates such as CTX310 for severe lipid disorders. A strong balance sheet—recently bolstered to around $2.4 billion in cash and marketable securities via a convertible-note offering—supports this breadth of programs, although dilution and an unprofitable, single-product revenue base remain key considerations for investors.
SANA Overview and Recent Performance
Sana Biotechnology is an engineered-cell company focused on the Hypoimmune (HIP) platform, which is designed to produce cells that can evade a patient's immune system without immunosuppression. Its lead program, SC451, is a stem-cell-derived pancreatic islet cell therapy targeting type 1 diabetes, with a regulatory filing (IND) planned as early as 2026. A second program, SG293, is an in vivo CAR T candidate for B-cell-related diseases. Sana's most recent results showed a narrowed net loss, reflecting tighter cost controls and lower R&D spending.
Recent price behavior has reflected both scientific progress and financing pressures. Sana raised approximately $69 million through an at-the-market (ATM) equity offering and received a $25 million investment from the Mayo Clinic, extending its cash runway toward mid-2027. These dilutive raises, together with a comparatively small cash balance of roughly $100 million at the start of the year, have weighed on shares even as analysts have maintained generally positive ratings and elevated price targets. Sana's relative performance has been volatile, consistent with its preclinical status and dependence on near-term clinical data.
Trending AI Robots
For investors seeking a more systematic approach to stock selection, Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. Tickeron hosts hundreds of AI trading bots that trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. These bots span a wide range of trading styles, strategies, timeframes, performance records, and statistics, and each manages its own distinct set of tickers. Because no single approach fits every market, reviewing the robots' documented metrics and recent performance can help traders identify tools aligned with their own objectives. Visit the Trending AI Robots page to explore the current lineup.
Head-to-Head Comparison
The clearest contrast between these two names is stage of maturity. CRSP generates recognized revenue through Casgevy and holds a multi-year cash runway, giving it lower financing risk and more visible near-term catalysts. SANA is entirely preclinical, with no product revenue and a shorter, recently extended runway; its appeal rests on the transformative potential of its HIP platform rather than any near-term sales.
Growth drivers also differ. CRSP's momentum is tied to commercial execution, label expansion, and a broadening pipeline spanning cardiovascular, autoimmune, and oncology indications. SANA's trajectory hinges on first-in-human proof-of-concept data for SC451 and SG293. On risk, both face clinical and regulatory uncertainty, but SANA carries additional financing and going-concern considerations. In sector exposure, both are biotechnology pure-plays; however, CRSP's marketed asset offers a degree of revenue diversification that SANA does not yet possess.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet durability, and catalyst breadth, Tickeron's AI would likely favor CRSP over SANA in the current environment. CRISPR Therapeutics offers a more stable positioning through commercial revenue, a substantial cash buffer, and multiple data readouts, which tend to support steadier trend signals. Sana's higher upside potential is balanced by greater volatility, dilution, and dependence on early-stage clinical outcomes. The verdict is probabilistic rather than definitive, reflecting that each stock serves a different risk profile rather than one being categorically superior.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and SANA is a Hold.
CRSP in +5.42% Uptrend, rising for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRSP advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CRSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 81 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for CRSP turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 37 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
CRSP moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for CRSP entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.772) is normal, around the industry mean (3.498). P/E Ratio (-10.631) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. CRSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SANA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for SANA turned positive on October 26, 2026. Looking at past instances where SANA's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SANA's RSI Indicator exited the oversold zone, 35 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where SANA advanced for three days, in 186 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SANA as a result. In 71 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SANA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
SANA broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SANA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.590) is normal, around the industry mean (3.498). P/E Ratio (-3.160) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. SANA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SANA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CRSP | ||
|---|---|---|
OUTLOOK RATING 1..100 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 96 | |
PRICE GROWTH RATING 1..100 | 69 | |
P/E GROWTH RATING 1..100 | 54 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CRSP | SANA | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 89% |
| Advances ODDS (%) | 14 days ago 82% | 3 days ago 79% |
| Declines ODDS (%) | 1 day ago 81% | 10 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRSP’s FA Score shows that 1 FA rating(s) are green while SANA’s FA Score has 1 green FA rating(s).
- CRSP’s FA Score: 1 green, 4 red.
- SANA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRSP’s TA Score shows that 3 TA indicator(s) are bullish while SANA’s TA Score has 4 bullish TA indicator(s).
- CRSP’s TA Score: 3 bullish, 6 bearish.
- SANA’s TA Score: 4 bullish, 4 bearish.
Price Growth
CRSP (@Biotechnology) experienced а -9.68% price change this week, while SANA (@Biotechnology) price change was -0.41% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was -3.33%, and the average quarterly price growth was -13.61%.
Reported Earning Dates
CRSP is expected to report earnings on Feb 16, 2027.
SANA is expected to report earnings on Mar 23, 2027.
Industries' Descriptions
@Biotechnology (+4.22% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
SANA and
Correlation & Price change
A.I.dvisor indicates that over the last year, SANA has been loosely correlated with EDIT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SANA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To SANA | 1D Price Change % | ||
|---|---|---|---|---|
| SANA | 100% | -1.42% | ||
| EDIT - SANA | 59% Loosely correlated | -8.91% | ||
| CRSP - SANA | 58% Loosely correlated | -9.77% | ||
| RCKT - SANA | 56% Loosely correlated | -3.16% | ||
| BEAM - SANA | 56% Loosely correlated | -6.92% | ||
| MGTX - SANA | 55% Loosely correlated | +1.37% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RESM | 23.55 | -0.08 | -0.34% |
| Columbia Research Enhanced Small Cap ETF (RESM) | |||
| BASG | 27.70 | -0.16 | -0.56% |
| Brown Advisory Sustainable Growth ETF (BASG) | |||
| SPRX | 33.32 | -0.28 | -0.83% |
| Spear Alpha ETF (SPRX) | |||
| EMSF | 34.14 | -0.30 | -0.86% |
| Matthews Emerging Markets Sustainable Future Active ETF (EMSF) | |||
| BPRE | 12.20 | -0.28 | -2.24% |
| Bluerock Private Real Estate Fund | |||